Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Dare Bioscience (DARE) over the last 11 years, with Q3 2025 value amounting to $18.0 million.

  • Dare Bioscience's Net Cash Flow rose 44667.24% to $18.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year increase of 53148.51%. This contributed to the annual value of $5.3 million for FY2024, which is 12205.88% up from last year.
  • Per Dare Bioscience's latest filing, its Net Cash Flow stood at $18.0 million for Q3 2025, which was up 44667.24% from -$5.3 million recorded in Q2 2025.
  • Over the past 5 years, Dare Bioscience's Net Cash Flow peaked at $36.5 million during Q3 2021, and registered a low of -$14.8 million during Q1 2023.
  • Its 5-year average for Net Cash Flow is $1.0 million, with a median of -$3.5 million in 2023.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 8712789.83% in 2021, then tumbled by 99692.41% in 2024.
  • Dare Bioscience's Net Cash Flow (Quarter) stood at $6.1 million in 2021, then plummeted by 196.9% to -$5.9 million in 2022, then soared by 41.06% to -$3.5 million in 2023, then skyrocketed by 230.5% to $4.5 million in 2024, then soared by 297.69% to $18.0 million in 2025.
  • Its Net Cash Flow was $18.0 million in Q3 2025, compared to -$5.3 million in Q2 2025 and -$5.4 million in Q1 2025.